Dr. Reddy's Laboratories Limited

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:53 16/07/2024 pm IST			5-day change	1st Jan Change
6,643 ^INR	-2.20%		+0.91%	+14.58%

04:47pm	Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading	MT
16/07	Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading	MT

Dr. Reddy's Laboratories Limited Announces Impairment Charges for the Third Quarter Ended December 31, 2021

January 28, 2022 at 08:58 pm IST

Dr. Reddy's Laboratories Limited announced impairment charges for the third quarter ended December 31, 2021. For the quarter, the company reported impairment of non current assets of INR 47 million compared to INR 5,972 million a year ago.

Latest news about Dr. Reddy's Laboratories Limited

Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading	08:17pm	MT
Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading	16/07	MT
Indian Equities Achieve New Closing Highs on Tuesday, Led by Realty, FMCG Goods Stocks	16/07	MT
Jefferies Forecasts Strong Fiscal Q1 for Indian Pharmaceuticals	16/07	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	15/07	MT
Dr. Reddy's Laboratories Limited Receives an Order from The Joint Commissioner,, Office of the Commissioner of Central Tax, Kochi Towards Tax Demand Including Interest and Penalty	15/07	CI
Asian Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading	10/07	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Trading	08/07	MT
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	05/07	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	03/07	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note	01/07	MT
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India	28/06	MT
Zydus and Dr. Reddy's Announces Licensing Agreement for Co-Marketing of Pertuzumab Biosimilar, a Critical Treatment for Breast Cancer Patients in India	28/06	CI
India plans incentives for diabetes, obesity drug makers in 2026, government official says	28/06	RE
Indian Equities Fall on Friday, Dragged Mainly by Banking Stocks	28/06	MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	27/06	MT
Dr. Reddy's to Acquire Haleon's Nicotine Replacement Therapy Business Outside US	27/06	MT
INDIA STOCKS-UltraTech Cement, Reliance power Indian shares to record highs	27/06	RE
Dr. Reddy's Laboratories to Acquire Nicotinell Portfolio From Haleon	26/06	MT
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update	26/06	DJ
Transcript : Dr. Reddy's Laboratories Limited - Special Call	26/06
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million	26/06	DJ
Haleon to sell nicotine replacement therapy business outside US for $633 mln	26/06	RE
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading	25/06	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	24/06	MT

Chart Dr. Reddy's Laboratories Limited

Duration

Period

More charts

Company Profile

Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).

Sector

Pharmaceuticals

Calendar

27/07/2024 - Q1 2025 Earnings Release

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Dr. Reddy's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6,643 INR

Average target price

6,164 INR

Spread / Average Target

-7.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DR. REDDY'S LABORATORIES LIMITED	+14.58%	13.24B
ELI LILLY AND COMPANY	+56.61%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.76%	363B
MERCK & CO., INC.	+15.01%	318B
ABBVIE INC.	+12.57%	299B
ASTRAZENECA PLC	+15.19%	243B
NOVARTIS AG	+16.68%	225B
AMGEN INC.	+15.55%	179B
PFIZER, INC.	+3.65%	167B

Other Pharmaceuticals